Post by
prophetoffactz on Aug 25, 2024 9:01am
Dr in charge of CSCI's avenanthramide trial welcomes new era
"The FDA's approval of colchicine confirms that we are entering a new era of patient care, now targeting inflammation as an underlying cause of atherosclerotic coronary artery disease," said Dr. Jean-Claude Tardif.